This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

oral semaglutide in obesity

Authoring team

In the UK, semaglutide tablets are now licensed for use in adults with a BMI of 30 or above, or who are overweight (BMI 27-30) with at least one weight-related comorbidity (1).

The starting dose is 1.5mg daily, increasing to 4mg, 9mg and 25mg with a minimum duration of one month at each dose level.

“..Patients currently treated privately with a 2.4 mg semaglutide injection once weekly can be transitioned straight to semaglutide 25 mg tablets once daily..” (1).

Reference:

  1. MHRA (June 11th 2026). First GLP-1 tablet for weight loss approved in the UK.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.